《中国期刊全文数据库》收录期刊
《中国核心期刊(遴选)数据库》收录期刊
《中文科技期刊数据库》收录期刊

外科研究与新技术(中英文) ›› 2025, Vol. 14 ›› Issue (4): 343-347.doi: 10.3969/j.issn.2095-378X.2025.04.009

• 论著 • 上一篇    下一篇

舒芬太尼皮下自控镇痛对居家癌痛患者镇痛效果及生存质量的影响

吴海滨, 赵春江, 何成辉, 张国强, 欧键莹   

  1. 佛山市南海区第四人民医院麻醉科,广东 佛山 528211
  • 收稿日期:2025-08-02 出版日期:2025-12-28 发布日期:2026-01-02
  • 作者简介:吴海滨(1984—),男,学士,副主任医师,从事临床麻醉工作;电子信箱:418291017@qq.com

Effect of sufentanil patient-controlled subcutaneous analgesia on analgesia and quality of life in patients with cancer pain at home

WU Haibin, ZHAO Chunjiang, HE Chenghui, ZHANG Guoqiang, OU Jianying   

  1. Department of Anesthesiology, Fourth People's Hospital of Nanhai District, Foshan City, Foshan 528211, Guangdong, China
  • Received:2025-08-02 Online:2025-12-28 Published:2026-01-02

摘要: 目的 探讨舒芬太尼皮下自控镇痛(PCSA)对居家癌痛患者镇痛效果及生存质量的影响。方法 选取2023年3月—2025年3月收治的85例癌症疼痛患者,采用随机数字表法分为对照组和观察组,每组各45例。观察组脱落5例,最终纳入40例。对照组患者采用口服吗啡镇痛,观察组患者采用舒芬太尼PCSA。比较两组患者治疗前后的生存质量[Karnofsky功能状态(KPS)评分]和疼痛情况[疼痛数字量表(NRS)评分],以及治疗过程中不良反应发生情况。结果 治疗后,两组患者NRS评分均低于治疗前(P<0.05);对照组NRS评分高于观察组,KPS评分低于观察组(P<0.05);对照组疼痛缓解率(71.11%)低于观察组(95.00%)(P<0.05)。观察组患者接受治疗后的不良反应发生率为30.00%,显著低于对照组的53.33%(P<0.05)。结论 舒芬太尼PCSA对居家癌痛患者镇痛效果好,可提高患者生存质量,且安全性高。

关键词: 舒芬太尼, 皮下自控镇痛, 癌痛, 镇痛效果, 生存质量

Abstract: Objective To investigate the effect of patient-controlled subcutaneous analgesia (PCSA) with sufentanil on analgesia and quality of life in patients with cancer pain at home. Methods A total of 85 patients with cancer pain who were admitted from March 2023 to March 2025 were selected and divided into a control group and an observation group according to the random number table method, with 45 cases in each group. Five cases dropped off in the observation group, and 40 cases were finally included in the observation group. Patients in the control group were treated with oral morphine for analgesia, and patients in the observation group were treated with sufentanil PCSA. The quality of life [Karnofsky performance scale (KPS)] and pain [numerical rating scale (NRS)] before and after treatment and the incidence of adverse reactions during treatment were compared between the two groups. Results After treatment, the NRS scores in both groups were lower than those before treatment (P<0.05). The NRS score of the control group was higher than that of the observation group, and the KPS score was lower of the control group than that of the observation group (P<0.05). The pain relief rate of the control group was 71.11%, which was lower than 95.00% of the observation group (P<0.05). The incidence of adverse reactions after treatment in the observation group was 30.00%, which was significantly lower than 53.33% in the control group (P<0.05). Conclusion Sufentanil PCSA has a good analgesic effect on patients with cancer pain at home, can improve the quality of life of patients, and has high safety.

Key words: Sufentanil, Subcutaneous self-controlled analgesia, Cancer pain, Analgesic effect, Quality of life

中图分类号: